Tirzepatide
A dual GIP+GLP-1 that pairs appetite reduction with improved insulin sensitivity — often chosen for stronger results.
Two signals at once, deeper response.
A once-weekly dual GIP+GLP-1 that combines appetite control with improved insulin sensitivity — often chosen when a stronger response is the goal.
How it works
Tirzepatide acts on two hormones at once — GLP-1 and GIP. That dual signal quiets appetite while also supporting how your body handles glucose, which is why response often deepens past the third month.
Your clinician maps out a titration schedule that prioritizes tolerance, moving up only when you're ready. Slower steps aren't a setback — they're usually why the dose sticks and the side effects don't.
What to expect
- CadenceOnce-weekly self-injection at home.
- DosingStarts at 2.5 mg/week and titrates up to 15 mg as tolerated.
- ResponseStrong appetite reduction, often more pronounced past month 3.
- DeliveryShips with a fine-gauge needle for a quick, comfortable weekly injection.
- Side-effect patternGI symptoms early in titration; a slower step-up typically improves tolerance.
Who it's for
Tirzepatide tends to be the right call when you want a stronger appetite response, when semaglutide has plateaued, or when metabolic health markers are part of the picture. It's not a fit for everyone — a short intake tells us which.
- Adults 18+ with a BMI of 27+ (or 25+ with a weight-related condition).
- Looking for a stronger response than semaglutide typically delivers.
- Comfortable with a once-weekly at-home injection and a patient titration.
- Interested in the metabolic and glucose-handling benefits alongside weight loss.
- —Personal or family history of medullary thyroid carcinoma or MEN 2.
- —History of pancreatitis, severe GI disease, or gastroparesis.
- —Currently pregnant, planning pregnancy, or breastfeeding.
- —Under 18, or with a BMI below the clinical threshold.
Your first 90 days
Tirzepatide response tends to deepen quarter over quarter. The first 90 days are less about hitting a maximum dose and more about arriving at one you tolerate cleanly.
- Days 1–30Onboarding at 2.5 mg
Your first weekly dose is 2.5 mg — a starter dose meant to acclimate your body, not to drive weight loss on its own. Expect a subtle drop in appetite and cravings by week two or three. Mild nausea early is common and usually settles.
- Days 31–60Step up to 5 mg
If tolerance is good, your clinician moves you to 5 mg — the first true therapeutic dose. Portions feel notably smaller and steady weekly change on the scale becomes the norm.
- Days 61–90Toward 7.5 mg
Most patients step to 7.5 mg by the end of month three. You'll have a clear sense of your response, and your clinician will decide whether to hold or continue stepping up in the months ahead.
What the average patient loses
Tirzepatide's dual-agonist mechanism tends to produce a deeper response than single-GLP-1 therapy. The numbers below reflect averages reported in the largest trials — a realistic reference, not a promise. Individual response varies with dose, adherence, food, and movement.
Early response as titration reaches a therapeutic dose.
Momentum deepens noticeably in months four through six.
Typical average at maintenance dose in long-term studies.
Averages are of total body weight loss and are drawn from published trials of tirzepatide (e.g., SURMOUNT program). Individual results vary and are not guaranteed.
Tirzepatide
A dual GIP+GLP-1 that pairs appetite reduction with improved insulin sensitivity — often chosen for stronger results.
